Concepts (285)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Membrane Glycoproteins | 36 | 2022 | 197 | 9.860 |
Why?
|
| Endometrial Neoplasms | 9 | 2021 | 64 | 3.590 |
Why?
|
| Neovascularization, Pathologic | 8 | 2022 | 122 | 2.350 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2021 | 781 | 2.170 |
Why?
|
| Precancerous Conditions | 6 | 2021 | 81 | 1.920 |
Why?
|
| Vascular Endothelial Growth Factor A | 7 | 2022 | 157 | 1.840 |
Why?
|
| Fetal Growth Retardation | 4 | 2019 | 51 | 1.570 |
Why?
|
| Neoplastic Stem Cells | 2 | 2020 | 74 | 1.300 |
Why?
|
| Glioblastoma | 3 | 2017 | 49 | 1.200 |
Why?
|
| Macrophages | 2 | 2021 | 431 | 1.140 |
Why?
|
| Antibodies, Monoclonal | 4 | 2020 | 282 | 1.140 |
Why?
|
| Endometrium | 4 | 2012 | 57 | 1.040 |
Why?
|
| Mice | 24 | 2021 | 5668 | 1.020 |
Why?
|
| Placenta | 4 | 2019 | 91 | 0.990 |
Why?
|
| Focal Adhesion Kinase 1 | 7 | 2015 | 18 | 0.970 |
Why?
|
| Endometrial Hyperplasia | 2 | 2021 | 3 | 0.930 |
Why?
|
| src-Family Kinases | 4 | 2014 | 42 | 0.930 |
Why?
|
| Cell Line, Tumor | 12 | 2021 | 2128 | 0.860 |
Why?
|
| Histocompatibility, Maternal-Fetal | 1 | 2021 | 1 | 0.810 |
Why?
|
| Decidua | 1 | 2021 | 8 | 0.810 |
Why?
|
| Immunoglobulin G | 3 | 2017 | 232 | 0.800 |
Why?
|
| Membrane Proteins | 6 | 2023 | 486 | 0.800 |
Why?
|
| Killer Cells, Natural | 2 | 2021 | 86 | 0.800 |
Why?
|
| Animals | 30 | 2021 | 14307 | 0.780 |
Why?
|
| Retinal Pigment Epithelium | 7 | 2022 | 30 | 0.750 |
Why?
|
| Xenograft Model Antitumor Assays | 6 | 2020 | 242 | 0.750 |
Why?
|
| Mice, Nude | 6 | 2020 | 323 | 0.740 |
Why?
|
| Female | 29 | 2021 | 19873 | 0.730 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2019 | 14 | 0.710 |
Why?
|
| Mice, Inbred BALB C | 8 | 2020 | 649 | 0.680 |
Why?
|
| Humans | 42 | 2023 | 34853 | 0.660 |
Why?
|
| Myelin Proteins | 3 | 2015 | 26 | 0.640 |
Why?
|
| Oxygen | 3 | 2020 | 193 | 0.640 |
Why?
|
| Antineoplastic Agents | 4 | 2015 | 756 | 0.620 |
Why?
|
| Adenocarcinoma | 3 | 2012 | 239 | 0.620 |
Why?
|
| Retinal Dehydrogenase | 1 | 2017 | 11 | 0.620 |
Why?
|
| Placental Insufficiency | 1 | 2017 | 2 | 0.620 |
Why?
|
| Isoenzymes | 1 | 2017 | 149 | 0.590 |
Why?
|
| Breast Neoplasms | 2 | 2020 | 1426 | 0.580 |
Why?
|
| Neoplasms | 2 | 2015 | 1033 | 0.520 |
Why?
|
| Signal Transduction | 7 | 2019 | 1802 | 0.500 |
Why?
|
| Tissue Array Analysis | 5 | 2017 | 65 | 0.500 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2014 | 32 | 0.480 |
Why?
|
| Immunoglobulin Fragments | 3 | 2012 | 7 | 0.470 |
Why?
|
| Pregnancy | 6 | 2021 | 1503 | 0.470 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2013 | 24 | 0.460 |
Why?
|
| Molecular Imaging | 1 | 2013 | 30 | 0.450 |
Why?
|
| Positron-Emission Tomography | 1 | 2013 | 79 | 0.440 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 2 | 2013 | 17 | 0.440 |
Why?
|
| Brain Neoplasms | 3 | 2017 | 105 | 0.410 |
Why?
|
| Integrin alpha6 | 1 | 2011 | 3 | 0.410 |
Why?
|
| Membrane Microdomains | 3 | 2011 | 46 | 0.400 |
Why?
|
| Eukaryotic Initiation Factor-3 | 1 | 2010 | 3 | 0.390 |
Why?
|
| Lung Neoplasms | 1 | 2014 | 336 | 0.360 |
Why?
|
| Embryo Implantation | 2 | 2006 | 29 | 0.350 |
Why?
|
| Neoplasms, Experimental | 1 | 2008 | 36 | 0.340 |
Why?
|
| Prognosis | 4 | 2021 | 707 | 0.330 |
Why?
|
| Cell Movement | 7 | 2019 | 545 | 0.320 |
Why?
|
| RNA, Messenger | 8 | 2020 | 1152 | 0.310 |
Why?
|
| Progesterone | 1 | 2008 | 117 | 0.310 |
Why?
|
| Blotting, Western | 9 | 2019 | 834 | 0.300 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 3 | 2020 | 81 | 0.300 |
Why?
|
| Corneal Neovascularization | 2 | 2019 | 6 | 0.300 |
Why?
|
| Ovarian Neoplasms | 1 | 2010 | 303 | 0.290 |
Why?
|
| Cell Proliferation | 4 | 2020 | 1149 | 0.290 |
Why?
|
| Immunohistochemistry | 5 | 2017 | 859 | 0.290 |
Why?
|
| Protein Binding | 4 | 2011 | 913 | 0.290 |
Why?
|
| Tissue Distribution | 3 | 2013 | 197 | 0.290 |
Why?
|
| Antibodies, Blocking | 2 | 2019 | 11 | 0.280 |
Why?
|
| Estradiol | 1 | 2008 | 244 | 0.280 |
Why?
|
| Disease Models, Animal | 4 | 2019 | 1300 | 0.280 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2005 | 12 | 0.270 |
Why?
|
| Aged, 80 and over | 4 | 2021 | 2333 | 0.260 |
Why?
|
| Caveolins | 2 | 2004 | 7 | 0.260 |
Why?
|
| Flow Cytometry | 6 | 2014 | 392 | 0.250 |
Why?
|
| Mice, Inbred C57BL | 5 | 2020 | 1530 | 0.250 |
Why?
|
| Immunotherapy | 2 | 2019 | 91 | 0.250 |
Why?
|
| Glycosylphosphatidylinositols | 1 | 2004 | 19 | 0.250 |
Why?
|
| Epithelial Cells | 4 | 2019 | 366 | 0.240 |
Why?
|
| Collagen Type I | 4 | 2012 | 27 | 0.240 |
Why?
|
| Gene Expression Profiling | 4 | 2019 | 600 | 0.240 |
Why?
|
| Melanoma | 2 | 2016 | 91 | 0.240 |
Why?
|
| Immune Tolerance | 2 | 2021 | 61 | 0.230 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2003 | 19 | 0.230 |
Why?
|
| Adult | 6 | 2021 | 11034 | 0.230 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2003 | 20 | 0.230 |
Why?
|
| Retinal Pigments | 1 | 2022 | 33 | 0.230 |
Why?
|
| Enzyme Activation | 3 | 2014 | 423 | 0.230 |
Why?
|
| Skin Neoplasms | 2 | 2016 | 151 | 0.220 |
Why?
|
| Aged | 5 | 2021 | 6448 | 0.220 |
Why?
|
| Disease Progression | 3 | 2021 | 580 | 0.220 |
Why?
|
| Eye | 1 | 2003 | 68 | 0.220 |
Why?
|
| Middle Aged | 7 | 2021 | 9642 | 0.220 |
Why?
|
| Infant, Newborn | 2 | 2022 | 871 | 0.220 |
Why?
|
| Pigment Epithelium of Eye | 3 | 2007 | 32 | 0.210 |
Why?
|
| Cell Line | 9 | 2020 | 1289 | 0.210 |
Why?
|
| Neoplasm Metastasis | 2 | 2020 | 211 | 0.200 |
Why?
|
| Transfection | 2 | 2017 | 496 | 0.200 |
Why?
|
| Apoptosis | 4 | 2020 | 1317 | 0.200 |
Why?
|
| Antigens, CD34 | 2 | 2019 | 18 | 0.200 |
Why?
|
| Mice, Knockout | 2 | 2021 | 897 | 0.200 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2023 | 147 | 0.190 |
Why?
|
| Models, Animal | 1 | 2021 | 131 | 0.190 |
Why?
|
| Trophoblasts | 2 | 2017 | 22 | 0.190 |
Why?
|
| Immunoprecipitation | 3 | 2011 | 126 | 0.190 |
Why?
|
| Retinal Neovascularization | 1 | 2020 | 9 | 0.190 |
Why?
|
| Liver Neoplasms | 1 | 2023 | 195 | 0.190 |
Why?
|
| Meningeal Neoplasms | 1 | 2020 | 4 | 0.190 |
Why?
|
| Immunity, Innate | 1 | 2021 | 135 | 0.190 |
Why?
|
| Meningioma | 1 | 2020 | 6 | 0.190 |
Why?
|
| Tetralogy of Fallot | 1 | 2019 | 6 | 0.190 |
Why?
|
| Retinopathy of Prematurity | 1 | 2020 | 25 | 0.180 |
Why?
|
| Tumor Cells, Cultured | 2 | 2020 | 480 | 0.180 |
Why?
|
| Vitreoretinopathy, Proliferative | 2 | 2011 | 3 | 0.180 |
Why?
|
| Green Fluorescent Proteins | 2 | 2017 | 200 | 0.180 |
Why?
|
| Protein Transport | 3 | 2011 | 286 | 0.170 |
Why?
|
| Gene Expression Regulation | 5 | 2019 | 968 | 0.170 |
Why?
|
| Protein Isoforms | 1 | 2019 | 121 | 0.170 |
Why?
|
| Limbus Corneae | 2 | 2019 | 3 | 0.170 |
Why?
|
| Heart Ventricles | 1 | 2019 | 121 | 0.170 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2019 | 445 | 0.170 |
Why?
|
| Fibrin | 1 | 2017 | 8 | 0.160 |
Why?
|
| Placentation | 1 | 2017 | 7 | 0.150 |
Why?
|
| Caveolin 1 | 3 | 2007 | 27 | 0.150 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2019 | 155 | 0.150 |
Why?
|
| Microarray Analysis | 1 | 2017 | 61 | 0.150 |
Why?
|
| Gene Knockout Techniques | 1 | 2017 | 46 | 0.150 |
Why?
|
| Chlamydia muridarum | 2 | 2009 | 104 | 0.150 |
Why?
|
| Mice, SCID | 1 | 2017 | 143 | 0.150 |
Why?
|
| Pericytes | 2 | 2016 | 21 | 0.150 |
Why?
|
| Uterus | 1 | 2017 | 54 | 0.150 |
Why?
|
| Glioma | 1 | 2017 | 76 | 0.150 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2019 | 283 | 0.150 |
Why?
|
| RNA, Small Interfering | 2 | 2017 | 391 | 0.150 |
Why?
|
| Fetal Nutrition Disorders | 1 | 2016 | 9 | 0.150 |
Why?
|
| Prenatal Nutritional Physiological Phenomena | 1 | 2016 | 14 | 0.150 |
Why?
|
| Microcirculation | 1 | 2016 | 39 | 0.140 |
Why?
|
| Interleukin-10 | 1 | 2016 | 69 | 0.140 |
Why?
|
| Up-Regulation | 2 | 2020 | 490 | 0.140 |
Why?
|
| Cell Adhesion | 3 | 2011 | 209 | 0.140 |
Why?
|
| Autophagy | 1 | 2016 | 111 | 0.130 |
Why?
|
| Peroxynitrous Acid | 1 | 2014 | 5 | 0.130 |
Why?
|
| Receptors, Cell Surface | 1 | 2015 | 135 | 0.120 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2014 | 41 | 0.120 |
Why?
|
| Integrins | 2 | 2011 | 49 | 0.120 |
Why?
|
| Molecular Mimicry | 1 | 2013 | 16 | 0.120 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2014 | 70 | 0.120 |
Why?
|
| Copper Radioisotopes | 1 | 2013 | 8 | 0.120 |
Why?
|
| Phosphorylation | 3 | 2011 | 878 | 0.110 |
Why?
|
| Retrospective Studies | 2 | 2011 | 1961 | 0.110 |
Why?
|
| Neoplasm Proteins | 1 | 2015 | 203 | 0.110 |
Why?
|
| Retina | 2 | 2007 | 255 | 0.110 |
Why?
|
| Protein Engineering | 1 | 2013 | 40 | 0.110 |
Why?
|
| Cardiovascular Diseases | 1 | 2019 | 628 | 0.110 |
Why?
|
| Gene Expression | 2 | 2017 | 639 | 0.110 |
Why?
|
| Microscopy, Confocal | 3 | 2012 | 210 | 0.110 |
Why?
|
| Survival Analysis | 1 | 2013 | 322 | 0.110 |
Why?
|
| Validation Studies as Topic | 1 | 2011 | 8 | 0.100 |
Why?
|
| Phenotype | 1 | 2014 | 650 | 0.100 |
Why?
|
| Analysis of Variance | 1 | 2013 | 528 | 0.100 |
Why?
|
| Menstrual Cycle | 1 | 2011 | 34 | 0.100 |
Why?
|
| Tumor Burden | 1 | 2011 | 79 | 0.100 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2014 | 605 | 0.100 |
Why?
|
| Wound Healing | 1 | 2011 | 69 | 0.100 |
Why?
|
| Nuclear Proteins | 1 | 2012 | 287 | 0.090 |
Why?
|
| Male | 5 | 2020 | 18870 | 0.090 |
Why?
|
| Immunoglobulins | 1 | 2009 | 36 | 0.090 |
Why?
|
| Genital Diseases, Female | 1 | 2009 | 37 | 0.090 |
Why?
|
| Antibody Specificity | 1 | 2008 | 75 | 0.080 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2008 | 195 | 0.080 |
Why?
|
| NIH 3T3 Cells | 2 | 2007 | 60 | 0.080 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2008 | 185 | 0.080 |
Why?
|
| Cells, Cultured | 3 | 2019 | 1442 | 0.080 |
Why?
|
| Transcription Factors | 1 | 2012 | 653 | 0.080 |
Why?
|
| Cell Membrane | 2 | 2007 | 360 | 0.070 |
Why?
|
| Collagen | 1 | 2007 | 162 | 0.070 |
Why?
|
| Chlamydia Infections | 1 | 2009 | 196 | 0.070 |
Why?
|
| Nerve Tissue Proteins | 2 | 2006 | 338 | 0.070 |
Why?
|
| RNA, Catalytic | 1 | 2006 | 5 | 0.070 |
Why?
|
| Disease-Free Survival | 1 | 2006 | 114 | 0.070 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2007 | 162 | 0.070 |
Why?
|
| Mice, Inbred Strains | 1 | 2006 | 117 | 0.070 |
Why?
|
| Down-Regulation | 2 | 2007 | 420 | 0.070 |
Why?
|
| Blastocyst | 1 | 2006 | 48 | 0.070 |
Why?
|
| Epithelium | 1 | 2005 | 74 | 0.070 |
Why?
|
| Survival Rate | 1 | 2006 | 310 | 0.070 |
Why?
|
| Fibronectins | 1 | 2005 | 65 | 0.070 |
Why?
|
| Extracellular Matrix | 1 | 2005 | 111 | 0.060 |
Why?
|
| Pulmonary Alveoli | 1 | 2004 | 26 | 0.060 |
Why?
|
| Transcription, Genetic | 1 | 2007 | 550 | 0.060 |
Why?
|
| Adaptor Protein Complex gamma Subunits | 1 | 2004 | 1 | 0.060 |
Why?
|
| Caveolin 2 | 1 | 2004 | 2 | 0.060 |
Why?
|
| Retroviridae | 1 | 2004 | 22 | 0.060 |
Why?
|
| Golgi Apparatus | 1 | 2004 | 25 | 0.060 |
Why?
|
| beta-Cyclodextrins | 1 | 2004 | 22 | 0.060 |
Why?
|
| Transferrin | 1 | 2004 | 31 | 0.060 |
Why?
|
| Heat-Shock Proteins | 1 | 2004 | 51 | 0.060 |
Why?
|
| Pilot Projects | 1 | 2006 | 628 | 0.060 |
Why?
|
| Molecular Chaperones | 1 | 2004 | 61 | 0.060 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 1 | 2003 | 5 | 0.060 |
Why?
|
| Lens Capsule, Crystalline | 1 | 2003 | 1 | 0.060 |
Why?
|
| G(M1) Ganglioside | 1 | 2003 | 13 | 0.060 |
Why?
|
| Sclera | 1 | 2003 | 6 | 0.060 |
Why?
|
| 3T3 Cells | 1 | 2003 | 58 | 0.060 |
Why?
|
| Ciliary Body | 1 | 2003 | 23 | 0.060 |
Why?
|
| Iris | 1 | 2003 | 30 | 0.060 |
Why?
|
| Optic Nerve | 1 | 2003 | 28 | 0.060 |
Why?
|
| Glypicans | 1 | 2023 | 8 | 0.060 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2003 | 53 | 0.060 |
Why?
|
| Immunoblotting | 1 | 2003 | 170 | 0.060 |
Why?
|
| Cornea | 1 | 2003 | 55 | 0.060 |
Why?
|
| Antibodies | 1 | 2003 | 135 | 0.060 |
Why?
|
| Cell Communication | 1 | 2003 | 93 | 0.050 |
Why?
|
| Electrocardiography | 1 | 2023 | 154 | 0.050 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 2 | 2012 | 35 | 0.050 |
Why?
|
| Endothelial Cells | 1 | 2004 | 296 | 0.050 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2000 | 22 | 0.050 |
Why?
|
| Lymphoma, B-Cell | 1 | 2000 | 22 | 0.050 |
Why?
|
| Hyperoxia | 1 | 2020 | 6 | 0.050 |
Why?
|
| Retinal Vessels | 1 | 2020 | 24 | 0.050 |
Why?
|
| E2F1 Transcription Factor | 1 | 2019 | 17 | 0.050 |
Why?
|
| Wnt Proteins | 1 | 2019 | 20 | 0.050 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2019 | 50 | 0.050 |
Why?
|
| Eye Burns | 1 | 2019 | 3 | 0.040 |
Why?
|
| Burns, Chemical | 1 | 2019 | 4 | 0.040 |
Why?
|
| Sodium Hydroxide | 1 | 2019 | 3 | 0.040 |
Why?
|
| Genome | 1 | 2019 | 117 | 0.040 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2019 | 29 | 0.040 |
Why?
|
| Gene Regulatory Networks | 1 | 2019 | 115 | 0.040 |
Why?
|
| Animals, Newborn | 1 | 2020 | 323 | 0.040 |
Why?
|
| Drosophila Proteins | 1 | 2000 | 162 | 0.040 |
Why?
|
| Inflammation | 2 | 2016 | 577 | 0.040 |
Why?
|
| Cell Cycle Proteins | 1 | 2000 | 220 | 0.040 |
Why?
|
| Ki-67 Antigen | 1 | 2017 | 32 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2017 | 269 | 0.040 |
Why?
|
| Plasminogen Activator Inhibitor 2 | 1 | 2016 | 3 | 0.040 |
Why?
|
| Blood Vessels | 1 | 2016 | 32 | 0.040 |
Why?
|
| Lectins | 1 | 2016 | 20 | 0.040 |
Why?
|
| Infant | 1 | 2019 | 1014 | 0.040 |
Why?
|
| Neoplasm Transplantation | 1 | 2016 | 114 | 0.040 |
Why?
|
| Luminescent Proteins | 1 | 2016 | 74 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2016 | 104 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2019 | 1422 | 0.030 |
Why?
|
| Energy Intake | 1 | 2016 | 160 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2019 | 1318 | 0.030 |
Why?
|
| Eating | 1 | 2016 | 152 | 0.030 |
Why?
|
| Mothers | 1 | 2016 | 164 | 0.030 |
Why?
|
| Neural Crest | 1 | 2013 | 23 | 0.030 |
Why?
|
| Single-Chain Antibodies | 1 | 2012 | 1 | 0.030 |
Why?
|
| Antigen-Antibody Reactions | 1 | 2012 | 20 | 0.030 |
Why?
|
| Camptothecin | 1 | 2012 | 20 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2013 | 117 | 0.030 |
Why?
|
| Menarche | 1 | 2012 | 13 | 0.030 |
Why?
|
| Peptide Library | 1 | 2012 | 25 | 0.030 |
Why?
|
| RNA | 1 | 2014 | 234 | 0.030 |
Why?
|
| Menopause | 1 | 2012 | 54 | 0.030 |
Why?
|
| Child | 1 | 2019 | 2875 | 0.030 |
Why?
|
| Collagen Type IV | 1 | 2011 | 48 | 0.030 |
Why?
|
| Molecular Sequence Data | 2 | 2007 | 1490 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2011 | 245 | 0.020 |
Why?
|
| Colony Count, Microbial | 1 | 2009 | 66 | 0.020 |
Why?
|
| Age Factors | 1 | 2012 | 1007 | 0.020 |
Why?
|
| Actins | 1 | 2009 | 142 | 0.020 |
Why?
|
| Integrin alpha1 | 1 | 2008 | 2 | 0.020 |
Why?
|
| Integrin alpha2 | 1 | 2008 | 3 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2008 | 105 | 0.020 |
Why?
|
| Models, Biological | 1 | 2011 | 642 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2008 | 75 | 0.020 |
Why?
|
| Gels | 1 | 2007 | 41 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2008 | 112 | 0.020 |
Why?
|
| Lysosomes | 1 | 2007 | 80 | 0.020 |
Why?
|
| Indoles | 1 | 2008 | 154 | 0.020 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2007 | 109 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2007 | 485 | 0.020 |
Why?
|
| Cytokines | 1 | 2009 | 569 | 0.020 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-3 | 1 | 2004 | 9 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2007 | 1124 | 0.020 |
Why?
|
| Risk Factors | 1 | 2012 | 3414 | 0.010 |
Why?
|
| Insect Proteins | 1 | 2000 | 37 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2004 | 1534 | 0.010 |
Why?
|
| Cell Division | 1 | 2000 | 296 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 2000 | 181 | 0.010 |
Why?
|
| Drosophila | 1 | 2000 | 133 | 0.010 |
Why?
|
| Base Sequence | 1 | 2000 | 932 | 0.010 |
Why?
|
| Rats | 1 | 2004 | 3261 | 0.010 |
Why?
|